Replies to post #205169 on Biotech Values

[DewDiligence]

ADXS—I recently bought a small position in two of the portfolios I manage and announced this in real-time on Twitter (

Bought $ADXS today in 2 accounts on this signal. https://t.co/Llma6ZHu4G

— Roy Friedman (@DewDiligence) October 4, 2016

).

Would be curious to hear in more detail what you like about them.

I like that ADXS is unliked—i.e. that, despite having multiple collaborations with Big Pharma/Big Bio, ADXS has been written off by many investors as a perpetual loser due to the blunders of prior management. (The current management was responsible for selling ImClone to LLY in 2004.)

Although I generally eschew investing in the overcrowded immuno-oncology arena, ADXS is probably the least followed serious company in this space, so I made an exception.